L. Smith
Net worth: 9 M $ as of 2024-03-30
Profile
L.
Mary Smith served as Vice President-Product Development at United Therapeutics Corp.
from 2014 to 2016.
She then worked as Executive Vice President-Gene Therapy at Bamboo Therapeutics, Inc. from 2016 to 2017.
Currently, she is the Chief Development Officer at Springworks Therapeutics, Inc. since 2020.
Dr. Smith received her undergraduate and doctorate degrees from the University of New Hampshire.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-24 | 183,752 ( 0.25% ) | 9 M $ | 2024-03-30 |
Former positions of L. Smith
| Companies | Position | End |
|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-12-14 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 2017-07-31 |
| UNITED THERAPEUTICS CORPORATION | Corporate Officer/Principal | 2016-05-31 |
Training of L. Smith
| University of New Hampshire | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
- Stock Market
- Insiders
- L. Smith